Marc Lichtenfeld

Articles by Marc Lichtenfeld

There seems to be a trend in financial media to publish long lists of stocks that were bought by successful hedge funds, but it doesn't do much good for individual investors. Here's the right way to follow the "smart money," without wasting your time on lists.

Sell in May and go away? Seems so -- stocks are off to a weak start this month, and some investment analysts are saying a pullback is due following April's strong rally. What's an investor to do? When the going gets tough, the tough buy consumer staples stocks.

This week, S&P warned there's a chance that the agency could lower the U.S.'s long-term credit rating. It's too hard to say which companies will be the winners and losers were a downgrade to occur, but these stocks in the small-cap healthcare sector should do just fine.

Gold bugs are celebrating, though they haven't thrown the victory party just yet. Many bullish investors believe the price of gold will reach $2,000 an ounce. But more than a century of data suggest that investing in stocks, rather than gold, is a better way to go.

Last month, the FDA approved Bristol-Myers Squibb's Ipilimumab drug for metastatic melanoma -- a breakthrough as there's no effective treatment for the deadly disease. But on the back of this news, the big picture for these five biotech companies is even more exciting.

If you're investing in stocks for the long term, buy stable companies with a track record of increasing their dividends -- and then reinvest those dividends -- to turbo-charge your portfolio's performance.